Globus Medical (GMED) Q2 2026 earnings review
Massive Margin Expansion Drives EPS Raise, Eclipsing Top-Line Noise
Globus Medical delivered a mixed top-line but a phenomenal bottom-line performance in Q2. Total revenue decelerated to 5.9% YoY growth ($789.6M), heavily masked by the ongoing strategic transition to robotics leasing and a planned turnaround in the Nevro segment. Excluding Nevro, the base business grew a healthy 9%. The real story is the relentless execution on profitability: adjusted gross margin expanded 200 basis points YoY to 69.4%, and adjusted EBITDA margin surged to 35.4%. This operating leverage drove Non-GAAP EPS up 56% to $1.34, prompting management to significantly raise full-year EPS guidance while maintaining revenue expectations.
🐂 Bull Case
Manufacturing synergies and operating leverage are taking hold faster than expected. Adjusted Gross Margin hit 69.4%, keeping the company well on track for its mid-70s long-term target, and driving record cash flow generation.
Excluding the M&A noise, base Globus revenues grew 9%. International Spine grew 14% as-reported (12% constant currency), proving the underlying implant demand remains intact.
🐻 Bear Case
After three consecutive quarters of ~10% growth, U.S. Spine decelerated to 7% in Q2. If this trend continues, the base business engine may be cooling.
Robotics and imaging sales collapsed 26% YoY to $26.1M. While management cites a strategic shift to leasing, it obscures true capital demand visibility and creates near-term revenue drag.
⚖️ Verdict: 🟢
Bullish. The optical deceleration in revenue is easily forgiven when underlying margins expand by 200 bps and EPS guidance is hiked aggressively. Management is executing perfectly on post-merger cost synergies.
Key Themes
Margin Expansion Masterclass
Globus continues to demonstrate elite cost control and synergy execution following the NuVasive merger. Adjusted Gross Profit Margin expanded to 69.4% (up from 67.4% a year ago). Adjusted EBITDA margin hit a staggering 35.4% (vs 28.0% YoY). This accelerating margin profile proves the company's manufacturing insourcing and supply chain optimization strategies are bearing significant fruit.
Enabling Technologies Revenue Reversing
Enabling Technologies revenue fell sharply by 25.8% YoY to $26.1M. Management has telegraphed this structural decline in prior quarters, attributing it to a strategic pivot away from upfront cash sales toward operating leases and rentals. While this may drive higher margin implant pull-through long-term, it creates a massive short-term headwind to reported segment sales and makes underlying hospital capital demand difficult to evaluate.
U.S. Spine Growth Moderating
U.S. Spine remains the company's critical profit engine. While 7% growth still marks a "fifth straight quarter of above-market revenue growth," it is a noticeable deceleration from the ~10% growth rate sustained throughout the second half of 2025 and Q1 2026. This requires careful monitoring to see if competitive rep recruiting tailwinds are fading.
International Spine Accelerating
International Spine growth hit 14% on an as-reported basis (12% constant currency). This is a strong positive signal that Globus is successfully overcoming legacy supply chain issues abroad and pushing deeper into key OUS markets, aligning with management's stated long-term goal of low-to-mid double-digit international growth.
Nevro Turnaround Dragging Top-Line
Total revenue grew 5.9%, but the base business (excluding Nevro) grew 9%. This explicitly implies the Nevro spinal cord stimulation business is contracting and dragging down consolidated growth. Management previously warned the asset would "get worse before it gets better" as they restructure the sales channel, and Q2 data confirms this painful transition is ongoing.
Other KPIs
Accelerating dramatically from $31.3 million in the prior year quarter. The massive cash generation is driven by surging net income, non-cash amortization add-backs, and tighter working capital management. This provides Globus with ample liquidity to fund its $500 million share repurchase program and future M&A without tapping debt markets.
Decelerating/Declining 25.3% YoY, but entirely due to a one-time accounting distortion. The prior year quarter (25Q2) included a massive $110.5 million bargain purchase gain related to the Nevro acquisition. Removing this optical noise, underlying operational profitability surged.
Guidance
Stable. The company maintained its full-year guidance, implying ~8-9% YoY growth from FY25. The refusal to raise the top-line guide despite an EPS hike confirms management's prior warnings: the shift to robotics leasing and Nevro's sales channel restructuring will cap near-term reported sales momentum.
Accelerating. Raised significantly from the prior range of $4.70 - $4.80. The new midpoint ($5.00) implies an ~25% YoY increase from FY25's $3.98. This aggressive hike signals immense confidence in the durability of the recent 200 bps gross margin expansion and SG&A leverage.
Key Questions
Nevro Turnaround Timing
Base business grew 9% while overall grew 6%, confirming a drag from Nevro. When exactly do you expect Nevro's revenue declines to bottom out, and have your internal targets for its return to growth shifted?
U.S. Spine Deceleration
U.S. Spine growth stepped down to 7% from the ~10% rate seen in recent quarters. Is this a function of tougher comps, a slowdown in competitive rep recruiting, or shifting market dynamics?
Enabling Tech Leasing Adoption
With Enabling Tech revenue down 26% YoY, can you quantify the underlying volume of placements (cash vs. lease) to help us understand true capital demand versus optical revenue deferral?
Gross Margin Ceiling
Adjusted gross margins reached an impressive 69.4%. With your long-term goal in the mid-70s, what are the specific manufacturing insourcing or supply chain levers remaining to bridge that gap over the next 12-24 months?